Evenity (Romosozumab) Cost in Texas 2026: Insurance, Medicaid, and Savings Options

Romosozumab-aqqg, marketed as Evenity, is a humanized monoclonal antibody that inhibits sclerostin and is administered as a monthly subcutaneous injection for up to 12 doses total. The FDA approved it in 2019 for postmenopausal women with osteoporosis at high fracture risk. A boxed warning restricts its use in patients who have experienced a heart attack or stroke within the past year. Unlike bisphosphonates such as alendronate, denosumab (Prolia), or teriparatide (Forteo), romosozumab works through a distinct mechanism, though clinicians often evaluate it alongside these alternatives when determining treatment sequences.

The core, verifiable answer

Romosozumab-aqqg, sold under the brand name Evenity, received FDA approval in April 2019 as a prescription medication for postmenopausal women with osteoporosis who face substantial fracture risk [FDA label]. Treatment involves two monthly subcutaneous injections administered by a healthcare provider, with therapy continuing for a maximum of 12 doses. The [FDA label] includes a boxed warning that contraindicates use in patients with myocardial infarction or stroke occurring within one year prior, based on cardiovascular safety concerns observed in clinical trials. Current pricing, insurance prior authorization policies, and coverage under Texas Medicaid formularies change frequently; readers should verify these details with relevant payers before making coverage or financial decisions, as this article did not confirm them against current sources at the time of publication.

What Evenity may cost in Texas

Specialty biologics like Evenity are typically priced by wholesale acquisition cost (WAC), which then flows through pharmacy benefit or medical benefit billing depending on where the injection is given. Earlier versions of this article cited a specific WAC figure (around $1,825 per monthly dose, roughly $21,900 for a full 12-dose course). That figure could not be re-verified against a current, dated pricing source for this revision, so it should be treated as an approximate historical reference point rather than a confirmed 2026 price. Actual patient cost depends heavily on:

• Whether the drug is billed under the pharmacy benefit or the medical benefit (Evenity is billed under HCPCS code J3111 when administered in a clinic or infusion setting)
• Whether the patient has met their deductible and what coinsurance percentage applies
• Whether the administering site (hospital outpatient, physician office, infusion center) negotiates a different rate than list price
• Whether the patient qualifies for manufacturer or hospital financial assistance

Because "buy and bill" billing means the provider purchases and administers the drug before the claim processes, patients often do not see their true out-of-pocket cost until after the injection. Anyone budgeting for a full course should ask the administering clinic for a written estimate before the first dose, not rely on a list price alone.

Does insurance in Texas cover Evenity?

Most large commercial insurers that operate in Texas cover Evenity under specialty pharmacy or medical benefit tiers, but coverage is conditioned on prior authorization. Typical prior-authorization documentation requested by payers includes a DEXA-confirmed T-score at or below a threshold such as -2.5, a history of osteoporotic fracture, and/or documented failure or intolerance of a first-line agent such as a bisphosphonate. Some plans additionally require a prior trial of denosumab. These are generalized patterns seen across specialty-drug utilization management, not a guarantee of any specific Texas insurer's current policy. A patient or clinic should pull the payer's actual medical policy for romosozumab before filing, since criteria vary by plan and change without notice.

Does Texas Medicaid cover Evenity?

Whether Evenity sits on the Texas Medicaid preferred drug list, and under what prior-authorization criteria, is a formulary detail that changes periodically and needs to be checked against the current HHSC Medicaid formulary or the patient's Medicaid managed care organization (MCO) rather than assumed from this article. What is a reasonable general expectation, based on how state Medicaid programs typically treat high-cost specialty osteoporosis biologics, is that romosozumab is more likely to require prior authorization and step therapy through Medicaid than through many commercial plans, and that a formulary exception request may be necessary for patients who meet high-fracture-risk criteria but do not clear a Medicaid step-therapy requirement. Clinicians filing an exception request should cite the patient's DEXA results, fracture history, and any prior bisphosphonate failure or intolerance, and should expect to reference current clinical guidance on anabolic therapy for very-high-risk patients rather than a specific numeric trial result unless that number has been checked against the original publication.

Manufacturer and foundation assistance programs

Amgen (Evenity's manufacturer, jointly marketed with UCB) has historically offered a co-pay savings program for commercially insured patients, and separately funds the Amgen Safety Net Foundation, which provides several Amgen products at no cost to income-qualifying uninsured or underinsured patients (amgensafetynetfoundation.com). The specific eligibility rules, income thresholds, and dollar caps for any co-pay card change over time and are set by the manufacturer, not by HealthRX.com, so the exact terms in effect for a given patient in 2026 need to be confirmed directly through the current program materials or the foundation's application process rather than assumed from a prior year's terms.

Verification checklist: stable facts vs. facts you must re-check

Use this checklist before quoting a cost or coverage detail to a patient. The left column is unlikely to change quickly and can generally be treated as reliable once confirmed against the FDA label. The right column changes on insurer, state, or manufacturer timelines and must be re-verified close to the date of use.

Stable, federally anchored facts (verify once against the FDA label)

• Generic name (romosozumab-aqqg), brand name (Evenity), and drug class (sclerostin-inhibiting monoclonal antibody)
• FDA-approved population: postmenopausal women with osteoporosis at high fracture risk
• Maximum treatment duration: 12 monthly doses
• Route and administration requirement: two subcutaneous injections given by a healthcare provider, not self-administered
• Boxed warning: contraindicated in patients with myocardial infarction or stroke within the past year
• Whether a follow-on antiresorptive agent is generally recommended after the 12-dose course (yes, per standard clinical practice, but the specific agent is a clinical decision, not a fixed rule)

Date-sensitive facts (re-check before every patient conversation or PA filing)

• Current WAC or cash price at the specific dispensing pharmacy
• Whether the patient's plan bills Evenity under pharmacy benefit or medical benefit (J3111)
• The specific insurer's current prior-authorization and step-therapy criteria
• Whether Evenity is on the Texas Medicaid preferred drug list this quarter, and the current MCO's exception process
• Current terms, eligibility, and dollar cap of any manufacturer co-pay program
• Current Amgen Safety Net Foundation income threshold and application requirements
• Whether a specific hospital financial assistance program's income cutoffs have changed for the current fiscal year
• Home-health or infusion-site administration fees, which vary by provider and are not standardized statewide

Is compounded romosozumab legal or available in Texas?

Texas 503A compounding pharmacies operate under the Texas State Board of Pharmacy and can, in principle, compound a patient-specific prescription. In practice, romosozumab is a large-molecule monoclonal antibody manufactured through recombinant DNA technology in mammalian cell lines, a process that ordinary 503A pharmacies are not equipped to replicate. FDA guidance on compounding biological products generally states that complex biologics are not appropriate candidates for compounding because of their molecular complexity (FDA guidance documents). As a practical matter, commercially available compounded romosozumab does not appear to exist from a legitimate Texas 503A pharmacy, and patients should treat any offer of "compounded Evenity" at a discount with significant skepticism, verifying licensure and product source directly with the Texas State Board of Pharmacy before proceeding.

Can Evenity be prescribed by telehealth in Texas?

Texas permits telemedicine to establish a valid physician-patient relationship, and a prescriber can reasonably evaluate DEXA results, labs, and history through a synchronous video visit before prescribing Evenity. What telehealth cannot do is administer the drug. Because Evenity must be injected by a healthcare provider in a clinical setting, a patient prescribed through telehealth still needs an in-person visit, at a clinic, infusion center, or through a home-health nursing service, for each of the 12 monthly doses. Confirm current telehealth prescribing rules with the Texas Medical Board if this is a compliance question for a practice, since state telehealth statutes are periodically amended.

What the trial evidence actually supports, and its limits

Romosozumab's approval rests on randomized trial evidence comparing it to placebo and to alendronate in postmenopausal women, generally known in the literature as the FRAME and ARCH trials, both published in the New England Journal of Medicine. These trials reported reductions in new vertebral fractures with romosozumab compared to placebo or to alendronate alone, and the ARCH trial also reported a numerically higher rate of serious cardiovascular events in the romosozumab arm, which led to the current boxed warning. Because this revision could not re-verify the original PMIDs against a live PubMed lookup, exact percentage figures for fracture reduction and cardiovascular event rates are not restated here as precise numbers; anyone citing a specific percentage to a patient or in a payer appeal should pull it directly from the original NEJM publications or the FDA label rather than from a secondary summary.

What is established: romosozumab builds bone through a dual mechanism (increasing formation while also reducing resorption) that is distinct from pure antiresorptive agents, and its benefit window is time-limited to the 12-dose course. What is plausible but not something this article independently confirmed: specific numeric comparisons of cost-effectiveness (such as an ICER value-based price threshold) attributed to a particular year's analysis. What is not established from the material reviewed here: any claim about how a specific Texas insurer or Texas Medicaid MCO will rule on an individual prior authorization, since that depends on plan-specific policy documents not verified in this draft.

Sequencing after the 12-dose course

Romosozumab's bone-forming effect is time-limited, and bone density gains are understood to diminish without a follow-on antiresorptive medication after the course ends. Standard clinical practice, reflected in professional guideline recommendations, is to transition patients to a bisphosphonate or to denosumab immediately after the final romosozumab dose. The choice between these follow-on options is a clinical decision that depends on renal function, fracture risk, and the patient's willingness to commit to a specific dosing schedule; it is not something this article can determine for an individual patient. Patients who have been taking denosumab should not stop it abruptly without a follow-on plan, since discontinuation has been associated with rebound vertebral fracture risk in the literature; this is a reason to keep any sequencing decision under the direction of the prescribing clinician rather than deciding independently.

Practical steps to reduce out-of-pocket cost

For commercially insured patients: confirm coverage with the insurer's specialty pharmacy team, submit prior authorization with DEXA results and fracture history, ask whether a manufacturer co-pay program applies before the first injection, and clarify whether the drug will be billed under the pharmacy or medical benefit, since assistance programs are often structured differently for each.

For Medicare Part B patients: co-pay cards from the manufacturer are generally not usable with federal health programs due to anti-kickback rules; the Amgen Safety Net Foundation and similar income-based charity programs may be an option, and a Medigap plan that covers Part B coinsurance can reduce the 20 percent coinsurance obligation on the Medicare-allowable amount.

For uninsured or underinsured Texas patients: apply to the manufacturer's patient assistance foundation before starting treatment, and ask Texas safety-net hospital systems about financial assistance programs, since retroactive coverage for treatment already received is rarely granted.

If coverage is denied, Texas Insurance Code Chapter 4201 provides a right to independent review organization (IRO) appeal for adverse utilization review decisions on top of the insurer's internal appeal process. A peer-to-peer conversation between the prescriber and the insurer's medical director, focused on the patient's specific fracture risk documentation, is often the fastest route to reversing a denial.

When to seek urgent care instead of troubleshooting cost

Cost and coverage problems are not urgent medical issues, but new chest pain, one-sided weakness, slurred speech, or other stroke or heart attack symptoms during Evenity treatment require emergency evaluation, not a call to the pharmacy or insurer. Given the boxed warning, any patient with a recent cardiovascular event should have that history reviewed with their prescriber before, not after, further doses are scheduled.

This article has not undergone qualified clinical review and is pending that review. Pricing, insurance, and Medicaid coverage details are date-sensitive and should be independently verified before being used for a coverage decision, prior authorization appeal, or financial commitment.